Skip to main content
Clinical Trials/NCT02964884
NCT02964884
Active, Not Recruiting
Phase 2

Neurobiology and Treatment of Reading Disability in NF1

Vanderbilt University1 site in 1 country120 target enrollmentNovember 1, 2016

Overview

Phase
Phase 2
Intervention
Lovastatin
Conditions
Neurofibromatosis Type 1
Sponsor
Vanderbilt University
Enrollment
120
Locations
1
Primary Endpoint
Woodcock Reading Mastery Test-III
Status
Active, Not Recruiting
Last Updated
10 months ago

Overview

Brief Summary

Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.

Detailed Description

Neurofibromitosis Type 1 (NF1) is a common autosomal dominant neurocutaneous syndrome. The most common concern of NF1 is learning disabilities (LDs). Approximately half of children with NF1 have LDs, the most common of which are reading disabilities (RDs).The purpose of this research is to gain a deeper understanding of the characteristics and treatment of RDs in NF1. The Investigator will evaluate four different groups (see list below) to determine if there are differential outcomes in these groups of children with NF+RD. The first two groups will consist of NF1 patients, and the second two groups will consist of participants with RDs but without NF1. 1. Reading tutoring program and a medication called Lovastatin (NF1 patients) 2. Reading tutoring program and no Lovastatin (placebo) (NF1 patients) 3. Reading tutoring program (RD participants) 4. Other Academic "Sham" tutoring (eligible to receive reading tutoring after study participation is complete) (RD participants)

Registry
clinicaltrials.gov
Start Date
November 1, 2016
End Date
January 1, 2027
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Laura Cutting

Principal Investigator

Vanderbilt University

Eligibility Criteria

Inclusion Criteria

  • This study will be open to all English speakers who meet eligibility criteria regardless of race, gender, minority or socioeconomic status. Inclusion criteria to be met are listed below:
  • Individuals ages 8-20 (all participants)
  • Documented NF-1 (NF patients only)
  • If female, participant is post-menarche (NF patients only)
  • If male, participant has reached Tanner Stage 2 (NF patients only)
  • Participant able to swallow capsule (NF patients only, may be confirmed via swallowability test, described below)
  • Participant's English is sufficient for school (all participants)
  • Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions B-D listed below:
  • A. Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability? Swallowability Assessment: We may ask patients to perform a capsule swallowability assessment prior to enrollment. We will ask subjects to attempt to swallow an empty capsule, matching the same size of the Lovastatin 20mg and 40mg capsules to be used in the study, to confirm swallowability. Patients will be provided with up to 2 capsules as needed to successfully perform the swallowability assessment. If the patient is unable to swallow the capsule, enrollment in the study may deferred or declined.
  • A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing:

Exclusion Criteria

  • Not provided

Arms & Interventions

NF1: Lovastatin + reading tutoring

Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks. And one week of intensive, one-on-one reading tutoring intervention

Intervention: Lovastatin

NF1: Lovastatin + reading tutoring

Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks. And one week of intensive, one-on-one reading tutoring intervention

Intervention: reading tutoring intervention

NF1: Placebo + reading tutoring

Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention

Intervention: reading tutoring intervention

NF1: Placebo + reading tutoring

Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention

Intervention: Placebo Oral Tablet

RD: Reading tutoring

Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention

Intervention: reading tutoring intervention

RD: Other Academic (sham) tutoring

Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading. These participants will have the opportunity to receive reading tutoring upon finishing study participation.

Intervention: Other Academic "sham" tutoring

Outcomes

Primary Outcomes

Woodcock Reading Mastery Test-III

Time Frame: 24 weeks

(WRMT-III; Forms A and B); Word Identification, Word Attack, and Passage Comprehension will be administered to assess word recognition accuracy, decoding accuracy, and comprehension. The WRMT-III and WJ-III correlate at .87, and at the item level show similar characteristics (e.g., containing 31% and 34% multisyllabic words, respectively).

Test of Silent Contextual Reading Fluency-2

Time Frame: 24 weeks

(TOSCRF-2; 91; Forms A, B, C, D). This test requires identifying as many words as possible in 3 min within a sentential context.

Comprehensive Test of Phonological Processing-2

Time Frame: 24 weeks

CTOPP-2 core subtests will be used to assess phonological processing, a known predictor of decoding and word recognition.

Woodcock Johnson Tests of Achievement IV

Time Frame: 24 weeks

WJ-IV (Forms A and B) Letter Word Identification, Word Attack, and Passage Comprehension subtests will be administered in order to assess word recognition accuracy, decoding accuracy, and comprehension.

Test of Word Reading Efficiency-2

Time Frame: 24 weeks

(TOWRE-2; Forms A, B, C, D) Sight Word Efficiency and Pseudoword Decoding will be used to assess real and pseudoword reading speed.

Delis Kaplan Executive Function System

Time Frame: 24 weeks

Sorting from the D-KEFS will be used to assess higher-level planning and shifting abilities.

Experimental Word and Pseudoword Lists

Time Frame: 24 weeks

At each visit, 2 word and 2 pseudoword lists (20 words each) will be administered. Word lists are matched on relevant characteristics (e.g., frequency, bigram frequency). Real word lists have already been developed and tested, and show high inter-correlations (r =.87-.97).

Visuospatial Learning and Memory, Morris Water Maze

Time Frame: 24 weeks

The child "hops" from square to square in the grid, repeated from various starting points. After landing on the target square, a fun goal pops up. The number of "hops" to reach the goal is measured. A control probe trial is given in which there is no goal.

Visuospatial Learning and Memory, Judgment of Line Orientation

Time Frame: 24 weeks

(JLO, Forms J and H)98 requires the judgment of spatial relationships between two lines compared to a reference of a protractor-like half-circle of 11 lines. The Investigator will create 4 forms from the two already existing by splitting each test in half by selecting every other item, a method used by others (Leach et al., 2003). This will allow us to generate 4 different versions of the JLO.

Clinical Evaluation of Language Fundamentals-Fifth Edition

Time Frame: 24 weeks

CELF-5 will be used to assess aspects of oral language (e.g., syntax, semantics, \& working memory).

Study Sites (1)

Loading locations...

Similar Trials